Photodynamic Therapy for Thyroid Cancer
Open accessThe DOI matches its Crossref record; 64 of the 67 references it cites were found in a registry or an index; 57 of the 142 sources its claims cite were checked for support.
Abstract
Background/Objectives: Thyroid cancer is the most common cancer of the endocrine system worldwide. Despite many available therapeutic options, the mortality rate of some subtypes, including anaplastic thyroid cancer, is still significant. Photodynamic therapy brings hope, which, through local activation of cell death pathways, as well as its effect on the immune system and vessels feeding the tumor, brings effects incomparable to classical methods. Photosensitizers particularly used in the case of thyroid cancer are hypericin, porphyrin, photophrin, radachlorin, or 5-aminolevulinic acid. Even better effects are achieved by administering sulforaphene, carboplatin, or genistein before therapy. Methods: For this research, we review articles in regard to provide a critical summary of the existing literature on thyroid cancer to explain the current state of scientific evidence on this topic. Conclusions: Photodynamic therapy is undoubtedly a technique of the future; the main advantages of which are low invasiveness, the possibility of combining with other treatment methods, or the possibility of outpatient use.
Overview
CoChat Summary
TL;DR
This narrative review summarizes the existing literature on thyroid cancer and the preclinical evidence for photodynamic therapy (PDT), concluding that PDT is a promising, minimally invasive approach whose use in thyroid cancer still requires further validation and standardization. The most studied photosensitizers are hypericin, porphyrin, photophrin, radachlorin, and 5-aminolevulinic acid, with enhanced effects when combined with sulforaphene, carboplatin, or genistein.
Key findings
- PDT with hypericin (HYP) reduced viability of anaplastic thyroid cancer cell lines in a concentration-dependent manner (most pronounced up to 10 µg/ml), increased intracellular ROS, decreased mitochondrial membrane potential, and almost completely reduced tumor weight and volume in mice; HYP's absorption peak was 593 nm.
- Porphyrin-HDL nanoparticle (PLP)-PDT (671 nm, 10 J/cm²) produced significant tumor cell apoptosis versus control (75.7% vs. 10.6% by TUNEL) in mouse and rabbit models, with preserved recurrent laryngeal nerve structure and no tumor cells on histology after day 53 in rabbits.
- 5-ALA PDT with a 633 nm diode laser reduced tumor size in undifferentiated thyroid cancer, with tumor growth delay of approximately 48% at 7 days, 55% at 14 days, and 51% at 21 days; tumor necrosis occurred in 20% of mice.
- Combining PDT with chemotherapy outperformed monotherapy: radachlorin-PDT plus carboplatin reduced live anaplastic cells to about 30% versus about 89% for carboplatin alone and about 80% for PDT alone, with complete inhibition at 0.05 mg/ml carboplatin plus 3.12 ng/ml radachlorin; ROS-positive cells were 81.6% with PDT versus 87.1% with combination, and mitochondrial membrane potential decreased 14.5% (carboplatin), 49.3% (PDT), and 80.6% (combination).
Methods
- Design: narrative literature review summarizing current information on thyroid cancer (incidence, genetics, histopathology, diagnosis, treatment) and PDT.
- Data sources: PubMed and Google Scholar databases; no systematic search strategy, inclusion criteria, or date range is reported.
- Content synthesis: descriptive summary of preclinical in vitro and animal studies of PDT in thyroid cancer, organized by photosensitizer and by enhancing agent.
Limitations
- Stated by the paper: "There are limited studies available on the use of PDT in the treatment of thyroid lesions"; PDT "requires further studies to validate and standardize its use"; the paper also notes a lack of specific standards and quality control for PDT.
- Evident from the text: this is a preprint explicitly marked "Not peer-reviewed version," and the review reports no systematic search protocol, risk-of-bias assessment, or quantitative synthesis; the cited evidence is predominantly preclinical (cell lines and animal models), with no clinical trials of PDT in thyroid cancer described.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Valid · 20 Not valid · 60 Not checked · 2 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“They proved that the degree of cytotoxicity correlated with the concentration of the photosensitizer, in this case photophrin.”
What the sources say
- Disputedcites [43] Bae, 2004, Photodynamic effects of Radachlorin on cervical cancer cells, Cancer Res. Treat. sourceExperimental — accuracy not yet measured
The in vitro results identify Radachlorin®, not Photofrin, as the photosensitizer tested in TC-1 cells. They report reduced cell viability with increasing light dose, not a demonstrated correlation between cytotoxicity and Photofrin concentration. Photofrin appears only in the Introduction’s list of photosensitizers. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moreover, despite maximizing their use and using different combinations, they are not always sufficient to achieve remission or at least stop the progression of the cancer, especially in the case of anaplastic thyroid cancer. [6]”
What the sources say
- Supportedcites [6] CShao, C., Li, Z., Zhang, C., Zhang, W., He, R., Xu, J., and Cai, Y. (2022). Optical diagnostic imaging and therapy for thyroid cancer. Mater. Today Bio, 17. source
The Introduction says anaplastic thyroid cancer has mortality close to 100% because effective therapy is lacking, and reports limited survival even among patients receiving multimodal therapy. The Radiotherapy & chemotherapy section adds that recommended drugs yield no survival benefit in advanced anaplastic thyroid cancer. Together, these passages support the claim that conventional treatments, including combinations, do not always halt the disease. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The main disadvantage of PDT is related to ROS, which causes pain by affecting nociceptors.”
What the sources say
- Could not verifycites [30] Tuttle, 2019, Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The passages on thyroid-cancer risk stratification and response to therapy do not address photodynamic therapy (PDT). Searches of our full-text copy for PDT, reactive oxygen species, nociceptors, and pain found no passage supporting the claimed mechanism. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Photodynamic therapy is a hope, which, used alone or in combination with previously used chemotherapy, gave promising results in preclinical studies. [6-10].”
What the sources say
- Supportedcites [6] CShao, C., Li, Z., Zhang, C., Zhang, W., He, R., Xu, J., and Cai, Y. (2022). Optical diagnostic imaging and therapy for thyroid cancer. Mater. Today Bio, 17. source
The Photodynamic therapy (PDT) section reports specific thyroid-tumor ablation with PDT in preclinical models. It also reports better inhibition of thyroid tumor growth and induction of apoptosis when chemotherapy is combined with PDT, supporting the claim's description of promising results. (LLM, conf=0.93)
- Not checked yetcites [7] Kaye, 2023, Management of Advanced Thyroid Cancer: Overview, Advances, and Opportunities, Am. Soc. Clin. Oncol. Educ. Book
- Not checked — no full text of the sourcecites [8] Biswas, 2015, Deregulation of EGFR/PI3K and activation of PTEN by photodynamic therapy combined with carboplatin in human anaplastic thyroid cancer cells and xenograft tumors in nude mice, J. Photochem. Photobiol. B source
- Not checked — no full text of the sourcecites [9] Kim, 2018, Hypericin-assisted photodynamic therapy against anaplastic thyroid cancer, Photodiagnosis Photodyn. Ther. source
- Not checked — no full text of the sourcecites [10] Biswas, 2014, Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells, Lasers Med. Sci. source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“low therapy costs compared to other methods in oncological treatment”
What the sources say
- Could not verifycites [6] CShao, C., Li, Z., Zhang, C., Zhang, W., He, R., Xu, J., and Cai, Y. (2022). Optical diagnostic imaging and therapy for thyroid cancer. Mater. Today Bio, 17. sourceExperimental — accuracy not yet measured
The Photodynamic therapy (PDT) section describes PDT’s clinical advantages but does not compare its treatment costs with other cancer treatments. The Challenges section calls surgery economical and says controlling medical costs is a challenge for optical treatment; it does not establish whether PDT costs less or more than other methods. Searches for comparative PDT costs found no supporting passage. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [28] Alexander, 2020, Thyroid Ultrasound: Diffuse and Nodular Disease, Radiol. Clin. N. Am. source
- Could not verifycites [30] Tuttle, 2019, Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-Up, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The paper’s Conclusions discuss risk-adapted management of differentiated thyroid cancer, but not photodynamic therapy or its cost. Searches of our full-text copy for photodynamic therapy/PDT and treatment costs found no passage comparing its cost with other oncological treatments. The indexed passages have no page numbers. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
66 more claims · 31 with their cited sources checked
Create a free account to see all 110 claims and to verify the 2 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 5
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 4. Application of Photodynamic Therapy in Thyroid Cancer
“The use of sulforaphene (SFE) - 4-methylsufinyl-3-butenyl isothiocyanate is also being studied in PDT.”
§ 4. Application of Photodynamic Therapy in Thyroid Cancer
“| C6H9NOS2 | 4-methylsulfinyl-3-butenyl isothiocyanate | | 16, 44, 45 | Sulforaphane |”
Citations
Cites
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
New photosensitizers for photodynamic therapy
Abrahamse, H., & Hamblin, M. R. (2016) · Biochemical Journal · doi:10.1042/bj20150942 · Cited by 2,033
Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions
Correia, J. H., Rodrigues, J. A., Pimenta, S., Dong, T., & Yang, Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091332 · Cited by 1,266
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Van Straten, D., Mashayekhi, V., De Bruijn, H., Oliveira, S., & Robinson, D. (2017) · Cancers · doi:10.3390/cancers9020019 · Cited by 1,012
Thyroid cancer incidence trends by histology in 25 countries: a population-based study
Miranda-Filho, A., Lortet-Tieulent, J., Bray, F., Cao, B., Franceschi, S., Vaccarella, S., & Dal Maso, L. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00027-9 · Cited by 601
Photodynamic Therapy: Current Status and Future Directions
Benov, L. (2015) · Medical Principles and Practice · doi:10.1159/000362416 · Cited by 421
Sharifi-Rad, J., Quispe, C., Imran, M., Rauf, A., Nadeem, M., Gondal, T. A., Ahmad, B., Atif, M., Mubarak, M. S., Sytar, O., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3268136 · Cited by 389
Alvarez, N., & Sevilla, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021023 · Cited by 254
Ciampi, R., Romei, C., Ramone, T., Prete, A., Tacito, A., Cappagli, V., Bottici, V., Viola, D., Torregrossa, L., Ugolini, C., et al. (2019) · iScience · doi:10.1016/j.isci.2019.09.030 · Cited by 239
Cited by
Kalender, D. S. Y., Kalender, M. E., & Topaloğlu, N. (2026) · Photobiomodulation Photomedicine and Laser Surgery · doi:10.1177/25785478261486643
Metadata
- Authors
- Inglot, J., Strzelczyk, J. K., Bartusik-Aebisher, D., & Aebisher, D.
- Affiliations
- University of Rzeszów (PL)
- Medical University of Silesia (PL)
- Department of Biochemistry and General Chemistry, Medical College, The Rzeszów University, 35-310 Rzeszów, Poland
- Venue
- BioMed
- Publisher
- MDPI AG
- Published
- 2025-03-14
- Volume
- 5
- Issue
- 1
- Pages
- 8
- ISSN
- 2673-8430 (ISSN-L)
- OpenAlex
- W4408522540
- Cited by
- 2
- References
- 67
- Citations by year
- 2026: 2
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BioMed (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- photodynamic therapy, thyroid cancer, anaplastic thyroid carcinoma, photosensitizers, hypericin, porphyrins, Radachlorin, 5-aminolevulinic acid, sulforaphene, carboplatin, genistein, tumor angiogenesis, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Photodynamic Therapy for Thyroid Cancer. https://app.cochat.ai/papers/10.3390/biomed5010008
- The paper
- Inglot, J., Strzelczyk, J. K., Bartusik-Aebisher, D., & Aebisher, D. (2025). Photodynamic Therapy for Thyroid Cancer. BioMed. https://doi.org/10.3390/biomed5010008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.